Sustainability conflicts in the blue economy: planning for offshore aquaculture and offshore wind energy development in Norway

Blue economy developments entail an industrialization of the world’s ocean and coastal areas, placing growing pressures on the marine environment and ecosystems. Moreover, the competition for ocean space and resources increases the likelihood for social conflicts. Marine spatial planning has been presented as a tool that can avoid or mitigate conflicts. However, there is a need for a more thorough analysis of the conflicts linked to the blue economy. The objective of this paper is to analyze characteristics of blue economy conflicts and how they are shaped by the institutional context and sustainability discourses. This study also explores perspectives on conflict management and pathways toward sustainable transformations in marine planning. Empirically, we use two case studies of blue growth industries in Norway: (1) offshore wind energy development and (2) offshore aquaculture development. Through these cases, we take a close look at the established principles and procedures which regulate conflicts. Our study shows how current blue economy conflicts are framed and handled through institutionalized practices of conflict management. Our findings are twofold. First, blue economy conflicts are not easily categorized through common conflict typologies (i.e., user-user, user-environment) but increasingly appear to be sustainability conflicts in which all actors use sustainability as a frame of reference for discussing possible and desirable futures. Second, conflicts are not necessarily a negative social process. In fact, conflicts often uncover unsustainable practices and create potential positive pathways for sustainable transformations.A correction to this article has been made. The file here is the updated version. Notes on the correction found here: https://link.springer.com/article/10.1007/s40152-023-00342-0publishedVersio

The effect of preoperative methylprednisolone on pulmonary function and pain after lung operations

AbstractThirty-six patients undergoing elective thoracotomy with pulmonary resection with the use of combined epidural and general anesthesia were randomized into a double-blind study to receive a single intravenous preoperative dose of methylprednisolone 25 mg/kg body weight or a placebo (saline solution). Postoperative pain relief consisted of epidural morphine 4 mg and paracetamol 1 gm three times a day for 4 days. Postoperative pulmonary function (peak expiratory flow rate, forced expiratory volume in first second, forced vital capacity) was evaluated on days 1, 2, 3, 4, and 7 and after 1 month. The value obtained after 1 month served as the control value. Pain score at rest and during cough was evaluated after 4 and 8 hours and on days 1, 2, 3, and 4. Pulmonary function was reduced after operation to the same degree in the steroid and placebo group: 42% versus 41% for forced expiratory volume in first second and 38% versus 39% for forced vital capacity, compared with control values after 1 month. Pain score was reduced in the steroid group after 4 hours and on day 1 during rest and after 4 and 8 hours and on day 2 during cough, compared with results in the placebo group ( p < 0.05). In the steroid group three patients underwent reoperation because of leakage through the chest wall incision. In conclusion, administration of a single preoperative dose of methylprednisolone did not affect the postoperative reduction in pulmonary function after thoracotomy despite attenuated pain response, and the results do not warrant steroid administration before lung operation. (J Thorac Cardiovasc Surg 1996;112:142-5

Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II)

ObjectivesThis study investigated the influence of the mechanical blood pump HeartMate II (HMII) (Thoratec Corporation, Pleasanton, California) on blood coagulation and platelet function.BackgroundHMII is an implantable left ventricular assist device used for the treatment of heart failure. Patients treated with HMII have increased bleeding tendencies.MethodsWe measured agonist-induced platelet aggregation in 16 patients on HMII support.ResultsThe von Willebrand factor (vWF)-dependent ristocetin-induced platelet aggregation was impaired in 11 of the 16 patients, of which 12 had experienced at least 1 minor or major bleeding episode. The impaired ristocetin-induced platelet aggregation was associated both with decreased specific activity of plasma vWF, presumably due to lack of high molecular weight vWF multimers, as well as with attenuated function of the platelets themselves.ConclusionsThe results imply that HMII treatment is associated with impaired platelet aggregation, which may contribute to an increased tendency to bleed